Indeed, Aslan et al (2020) previously tested the efficacy of colony‐stimulating factor 1 receptor (CSF1R) blockade using a neutralizing antibody to target TAMs and demonstrated improved treatment responses to ICB in a glioma model. The gene discussed is CSF1R; the disease is glioma.